Comments
Aurobindo Pharma Ltd has received final approval from the US Food & Drug Administration (USFDA) to manufacture Sevelamer Carbonate oral suspension.
Sevelamer Carbonate oral suspension is a therapeutic equivalent generic version of Genzyme’s Renvela oral suspension.
The product is being launched immediately. It is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis, the Hyderabad-based Aurobindo said in release.
The approved product has an estimated market size of $140 million for the 12 months ending April 2017, according to IMS.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.